Biological Products clinical trials
A group of medicines. Vaccines (74 studies) is counted on its own page; this page counts the studies that name Biological Products itself.
How each study uses Biological Products is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Biological Products studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Medicines filed under Biological Products
As reviewed, so not every one. Each counts its studies on its own page, not here.
- Vaccines
- 74
Studies by the year they started
27 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2017 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 17
West China Hospital (2) · National Environment Agency, Singapore (2) · Immune Cell, Inc. (2) · AskBio Inc (1) · Bruce Cree (1) · BioNTech SE (1) · University Hospital, Lille (1) · Steven E Arnold, MD (1)
Often tested with
Tested in the same studies.
Vaccines (3) · Afatinib (2) · Tislelizumab (1) · BNT162 Vaccine (1) · BCG Vaccine (1) · Recombinant Human Papillomavirus 11-valent Vaccine (1) · Melphalan (1) · Inodiftagene vixteplasmid (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test Biological Products.
- May 2027A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell CarcinomaPhase 1/2 · West China Hospital
- Jul 2027Impact of IIT-SIT on Dengue ClustersNot applicable · National Environment Agency, Singapore
- Aug 2027Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid TumorsPhase 1 · Kyushu University
- Oct 2027Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological TherapyPhase 4 · Universitaire Ziekenhuizen KU Leuven
Studies
Open first, then newest update. How each study uses Biological Products is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 27
- Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA TreatmentRecruitingNot applicableHospices Civils de LyonNCT07213323Written as Probiotics (Natural product)
- Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid TumorsRecruitingPhase 1Kyushu UniversityNCT05608148Written as Biological
- Tumor-Specific T-Cells (cCTL:GL01) for Advanced Gastrointestinal CancerNot yet recruitingPhase 1The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07735065Written as Biological/Vaccine
- Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological TherapyRecruitingPhase 4Universitaire Ziekenhuizen KU LeuvenNCT05169593Written as Biological Drug
- An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantRecruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT06832410Written as Biological/Vaccine
- Impact of IIT-SIT on Dengue ClustersRecruitingNot applicableNational Environment Agency, SingaporeNCT06894901Written as Biological (Male Wolbachia-infected Aedes aegypti)
- CD30 Targeted CAR-T in Treating CD30-Expressing LymphomasRecruitingPhase 1Immune Cell, Inc.NCT03383965Written as ICAR30 T cells
- A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and LeukemiaRecruitingPhase 1Immune Cell, Inc.NCT03383952Written as ICAR19 CAR-T cells
- A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)Active, not recruitingPhase 2AskBio IncNCT06285643Written as AAV2-GDNF gene therapy
- A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV VirusWithdrawnPhase 1West China HospitalNCT06741982Written as Lysogenic HSV virus.
- Clinical Trial of GAIA-102 for Advanced and Relapse NSCLCTerminatedPhase 1/2GAIA BioMedicine Inc.NCT05207371Written as Biological
- A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple SclerosisActive, not recruitingPhase 1Bruce CreeNCT06451159Written as KYV-101 (Biological) - 0.33 ×10^8 cells
- A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell CarcinomaActive, not recruitingPhase 1/2West China HospitalNCT07010120Written as Lysogenic HSV virus.
- Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy ChildrenCompletedPhase 3BioNTech SENCT04816643Written as Biological/Vaccine: BNT162b2 10mcg
- Biological Meshes in Infected Fields: a Randomized Controlled TrialCompletedPhase 3University Hospital, LilleNCT01594450Written as Biological mesh
- Impact of Project Wolbachia - Singapore on Dengue IncidenceCompletedNot applicableNational Environment Agency, SingaporeNCT05505682Written as Biological (Male Wolbachia-infected Aedes aegypti)
- A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate ADCompletedPhase 2Steven E Arnold, MDNCT05004688Written as Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
- Validation of the In-utero Transmission of ProbioticsCompletedPhase 2Centre de recherche du Centre hospitalier universitaire de SherbrookeNCT04050189Written as Natural products: Probiotics
- Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA TrialWithdrawnPhase 2Longeveron Inc.NCT02587572Written as Peripheral Intravenous (IV) infusion of LMSCs
- Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)CompletedPhase 2National Vaccine and Serum Institute, ChinaNCT04436133Written as Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
Codes
What other systems call Biological Products · ClinicalTrials.gg INT007075
- MeSH (NLM) D001688Biological ProductsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D001688 | Biological Products | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.